Advertisement
Canada markets closed

  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CAD/USD

    0.7270
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.74
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    84,734.88
    -3,368.27 (-3.82%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,383.90
    -4.50 (-0.19%)
     

  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     

  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     

  • NASDAQ futures

    17,706.25
    +47.75 (+0.27%)
     

  • VOLATILITY

    18.21
    -0.19 (-1.03%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • NIKKEI 225

    37,948.56
    -13.24 (-0.03%)
     

  • CAD/EUR

    0.6805
    +0.0003 (+0.04%)
     

SBTX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Silverback Therapeutics, Inc.

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 29, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Silverback Therapeutics, Inc. ("Silverback Therapeutics") (NASDAQ: SBTX) . This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive..

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/silverback-therapeutics-inc-loss-submission-form?prid=21706&wire=5



Allegations against SBTX include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

ADVERTISEMENT

If you suffered a loss in Silverback Therapeutics you have until January 4, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105764